Viracta Therapeutics (VIRX) Insider Trading & Ownership → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free VIRX Stock Alerts $0.84 +0.04 (+5.00%) (As of 05/15/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Viracta Therapeutics (NASDAQ:VIRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.42%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$25,526.06Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$14,599.75 Get VIRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Viracta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VIRX Insider Buying and Selling by Quarter Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WayNanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront!See how with its ongoing expansion and development Viracta Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/27/2024Daniel R ChevallardCFOSell3,405$0.73$2,485.65 11/30/2023Mark RotheraCEOBuy52,094$0.49$25,526.06 11/28/2023Daniel R ChevallardCFOSell3,720$0.50$1,860.00 8/28/2023Daniel R ChevallardCFOSell3,512$1.45$5,092.40 5/25/2023Daniel R ChevallardCFOSell3,635$1.42$5,161.70 (Data available from 1/1/2013 forward) VIRX Insider Trading Activity - Frequently Asked Questions Who is on Viracta Therapeutics's Insider Roster? The list of insiders at Viracta Therapeutics includes Daniel R Chevallard, Ivor Royston, Lisa Rojkjaer, and Mark Rothera. Learn more on insiders at VIRX. What percentage of Viracta Therapeutics stock is owned by insiders? 7.42% of Viracta Therapeutics stock is owned by insiders. Learn more on VIRX's insider holdings. Which Viracta Therapeutics insiders have been buying company stock? The following insider purchased VIRX shares in the last 24 months: Mark Rothera ($25,526.06). How much insider buying is happening at Viracta Therapeutics? Insiders have purchased a total of 52,094 VIRX shares in the last 24 months for a total of $25,526.06 bought. Which Viracta Therapeutics insiders have been selling company stock? The following insiders have sold VIRX shares in the last 24 months: Daniel R Chevallard ($51,778.61), Ivor Royston ($78,657.59), and Lisa Rojkjaer ($22,252.10). How much insider selling is happening at Viracta Therapeutics? Insiders have sold a total of 63,811 Viracta Therapeutics shares in the last 24 months for a total of $152,688.30 sold. More Insider Trading Tools from MarketBeat Related Companies: SPRB Insider Selling ACXP Insider Selling FBIO Insider Selling NRXP Insider Selling BCTX Insider Selling MRKR Insider Selling APRE Insider Selling CASI Insider Selling ACST Insider Selling JAN Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 4 Small-Cap Energy Stocks Insiders are Buying 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are Buying This page (NASDAQ:VIRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.